EMA advises switching patients off Genzyme's Fabrazyme because of shortages
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has advised physicians to consider switching patients with Fabry's disease from Genzyme's Fabrazyme (agalsidase beta) onto alternative enzyme replacement therapies such as Shire's Replagal (agalsidase alfa) in light of continued product shortages.